Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients.

Black JL, Litzow MR, Hogan WJ, O'Kane DJ, Walker DL, Lesnick TG, Kremers WK, Avula R, Ketterling RP.

Leuk Res. 2012 Jan;36(1):59-66. doi: 10.1016/j.leukres.2011.06.020. Epub 2011 Jul 8.

PMID:
21741706
2.

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.

Xie H, Griskevicius L, Ståhle L, Hassan Z, Yasar U, Rane A, Broberg U, Kimby E, Hassan M.

Eur J Pharm Sci. 2006 Jan;27(1):54-61. Epub 2005 Sep 23.

PMID:
16183265
3.

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV.

Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23.

4.

Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.

Rocha V, Porcher R, Fernandes JF, Filion A, Bittencourt H, Silva W Jr, Vilela G, Zanette DL, Ferry C, Larghero J, Devergie A, Ribaud P, Skvortsova Y, Tamouza R, Gluckman E, Socie G, Zago MA.

Leukemia. 2009 Mar;23(3):545-56. doi: 10.1038/leu.2008.323. Epub 2008 Nov 13.

PMID:
19005482
5.

Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers.

Ellison CA, Abou El-Ella SS, Tawfik M, Lein PJ, Olson JR.

J Toxicol Environ Health A. 2012;75(4):232-41. doi: 10.1080/15287394.2012.641201.

6.

Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.

Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, Minami H.

Pharmacogenet Genomics. 2007 Jun;17(6):431-45.

PMID:
17502835
7.

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.

Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H.

J Hum Genet. 2009 Oct;54(10):564-71. doi: 10.1038/jhg.2009.79. Epub 2009 Aug 21.

PMID:
19696793
8.

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.

Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, De Zoysa JZ, Tingle MD.

Br J Clin Pharmacol. 2010 Dec;70(6):844-53. doi: 10.1111/j.1365-2125.2010.03789.x.

9.

Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.

Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, Eap CB.

Clin Pharmacol Ther. 2005 Dec;78(6):593-604.

PMID:
16338275
10.

Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.

Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A.

Pharmacogenomics J. 2003;3(1):53-61.

PMID:
12629583
11.

Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.

Singh G, Saxena N, Aggarwal A, Misra R.

J Rheumatol. 2007 Apr;34(4):731-3. Epub 2007 Feb 15.

PMID:
17407229
12.

Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.

Winoto J, Song H, Hines C, Nagaraja H, Rovin BH.

Clin Nephrol. 2011 May;75(5):451-7.

PMID:
21543025
13.

CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility.

Yuan ZH, Liu Q, Zhang Y, Liu HX, Zhao J, Zhu P.

Ann Hematol. 2011 Mar;90(3):293-9. doi: 10.1007/s00277-010-1085-z. Epub 2010 Sep 28.

PMID:
20878158
14.

Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility.

Berköz M, Yalin S.

Leuk Res. 2009 Jul;33(7):919-23. doi: 10.1016/j.leukres.2008.11.014. Epub 2009 Jan 13.

PMID:
19144407
15.

Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations.

Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D.

J Anal Toxicol. 2011 Sep;35(7):431-7.

16.

Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans.

Arenaz I, Vicente J, Fanlo A, Vásquez P, Medina JC, Conde B, González-Andrade F, Sinués B.

Fundam Clin Pharmacol. 2010 Apr;24(2):247-53. doi: 10.1111/j.1472-8206.2009.00753.x. Epub 2009 Aug 14.

PMID:
19682083
17.

OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths.

Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D.

Clin Pharmacol Ther. 2010 Sep;88(3):383-9. doi: 10.1038/clpt.2010.127. Epub 2010 Jul 28.

PMID:
20668445
18.

Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles.

Restrepo JG, Martínez C, García-Agúndez A, Gaviria E, Laguna JJ, García-Martín E, Agúndez JA.

Pharmacogenet Genomics. 2011 Dec;21(12):773-8. doi: 10.1097/FPC.0b013e32834b3efc.

PMID:
21886015
19.

Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.

Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG.

J Pharmacol Exp Ther. 2003 Dec;307(3):906-22. Epub 2003 Oct 9.

20.

Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation.

Melanson SE, Stevenson K, Kim H, Antin JH, Court MH, Ho VT, Ritz J, Soiffer RJ, Kuo FC, Longtine JA, Jarolim P.

Am J Hematol. 2010 Dec;85(12):967-71. doi: 10.1002/ajh.21889. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk